Phase ll study of Panitumumab for advanced colorectal cancer which has prior therapy of Bevacizumab
Phase 2
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000005179
- Lead Sponsor
- Yokohama city university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Advanced pleural effusion, ascites 2) CNS metastases 3) Infection 4) Diarrhea (watery stool) 5) Heart disease as a clinical problem 6) Severe complications (intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, it is difficult to control diabetes, heart failure, kidney failure, liver failure etc.) 7) Active double cancer 8) Severe mental disorder 9) Irinotecan, oxaliplatin, panitumumab history of hypersensitivity to 10) Treatment with atazanavir sulfate 11) Pregnant and lacting women 12) Severe drug allergy 13) Judged unfit to by doctors in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate:RR
- Secondary Outcome Measures
Name Time Method Safety Overall survival :OS Progression free survival :PFS